Evidence map›Paper›PMID 42368383›Full record

ArticleNeuro-oncology advances

Medulloblastoma immune microenvironment resembles early brain development and reveals novel basophil- B cell- associated signatures.

Guy Dumanis, Dvir Aran, Ruty Mehrian-Shai

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Guy DumanisArrow Program for Medical Research Education, Sheba Medical Center, Tel Hashomer, Israel.
Dvir AranFaculty of Biology, Technion-Israel Institute of Technology, Israel.ORCID https://orcid.org/0000-0001-6334-5039
Ruty Mehrian-ShaiScojen Institute for Synthetic Biology, Reichman University, Harzliya, Israel (R.M.-S.).ORCID https://orcid.org/0000-0003-3961-0693

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Medulloblastoma (MB) is the most common malignant pediatric brain tumor; yet, the mechanisms underlying immune evasion remain poorly understood. Since the developing brain's immune environment naturally promotes tissue tolerance and remodeling, we hypothesized that MB may exploit developmental immune programs to escape surveillance. Here, we aimed to characterize the immune microenvironment of MB compared to healthy brain tissue across different developmental stages. Methods: We analyzed RNA-sequencing data from 124 MB tumors and 47 control brain samples spanning postconception weeks (PCWs) 8-37 through adulthood. Using xCell and DeconRNAseq, we quantified enrichment scores for 34 immune cell types and compared their profiles. Results: MB tumors exhibited a distinct immune profile most similar to PCW controls among all age groups tested ( Conclusions: MB displays an immune microenvironment resembling early developmental stages, characterized by elevated basophils and memory B cells alongside reduced conventional immune surveillance mechanisms. These findings suggest that MB may co-opt developmental immune tolerance programs and highlight basophil - B cell interactions as potential therapeutic targets. The developmental similarity provides new insights into MB pathogenesis and immune evasion strategies.

Indexed as

B cellsmedulloblastomapediatric brain tumortumor microenvironment

Identifiers

PMID42368383
PMCPMC13294674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.